Back to search

Article

Opportunities for cost reduction of current first-line WHO-recommended oral antiretroviral therapy: replacing tenofovir disoproxil fumarate with tenofovir alafenamide

2026-03-13

Abstract excerpt

<h4>Introduction</h4> Dolutegravir-based first-line antiretroviral therapy (tenofovir disoproxil fumarate, lamivudine, and dolutegravir; TLD) has delivered substantial clinical and public health benefits. However, sharply decreasing funding for HIV programmes necessitates cost reduction within current treatment guidelines. We evaluated whether replacing tenofovir disoproxil fumarate with tenofovir alafenamide (TA...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b269de8c-f7b9-5608-8b9b-58d2424e321a
DOI
10.64898/2026.03.12.26348214
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Opportunities for cost reduction of current first-line WHO-recommended oral antiretroviral therapy: replacing tenofovir disoproxil fumarate with tenofovir alafenamideDOI 10.64898/2026.03.12.26348214
The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.Semantic proximity
Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.Semantic proximity
Cost and cost-effectiveness of Hepatitis C virus self-testing in four settings: an economic evaluationSemantic proximity
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity
Impact of Generic Antiretroviral Drugs Introduction on Pharmaceutical Expenditure Patterns in the Netherlands: A Six-Year Retrospective Database Analysis from 2016 to 2022Semantic proximity
Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan womenSemantic proximity
The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2Semantic proximity
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialSemantic proximity
Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals in the Indo-PacificSemantic proximity
Estimated global cost of treating COVID-19, HIV, Hepatitis B and Hepatitis C with approved effective oral medicationsSemantic proximity
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.Semantic proximity
Predicting emergent Dolutegravir resistance in South Africa: A modelling studySemantic proximity
Select a neighboring publication to make it the new centre.